Swetha Kambhampati , Geoffrey Shouse , Alexey V. Danilov
{"title":"Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma","authors":"Swetha Kambhampati , Geoffrey Shouse , Alexey V. Danilov","doi":"10.1016/j.blre.2023.101099","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>There have been significant advancements in the management of follicular lymphoma<span><span> (FL), the most common indolent lymphoma. These include immunomodulatory agents such as lenalidomide, </span>epigenetic<span> modifiers (tazemetostat), and phosphoinotiside-3 kinase inhibitors<span> (copanlisib). The focus of this review is T cell-engager therapies, namely </span></span></span></span>chimeric antigen receptor<span> (CAR) T-cell therapy and bispecific antibodies, have recently transformed the treatment landscape of FL. Two CAR </span></span>T cell<span><span><span> products, axicabtagene ciloleucel<span> (axi-cel) and tisagenlecleucel (tisa-cel), and one bispecific antibody, </span></span>mosunetuzumab, recently received FDA approvals in FL. Several other new immune effector </span>drugs are being evaluated and will expand the treatment armamentarium. This review focuses on CAR T-cell and bispecific antibody therapies, details their safety and efficacy and considers their evolving role in the current treatment landscape of FL.</span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000607","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
There have been significant advancements in the management of follicular lymphoma (FL), the most common indolent lymphoma. These include immunomodulatory agents such as lenalidomide, epigenetic modifiers (tazemetostat), and phosphoinotiside-3 kinase inhibitors (copanlisib). The focus of this review is T cell-engager therapies, namely chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies, have recently transformed the treatment landscape of FL. Two CAR T cell products, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), and one bispecific antibody, mosunetuzumab, recently received FDA approvals in FL. Several other new immune effector drugs are being evaluated and will expand the treatment armamentarium. This review focuses on CAR T-cell and bispecific antibody therapies, details their safety and efficacy and considers their evolving role in the current treatment landscape of FL.
期刊介绍:
Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.